The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.

Adding immunotherapy to chemo may boost pCR and downstaging rates in the neoadjuvant setting for muscle-invasive bladder ...

SVR10 at week 12 with pacritinib was linked to longer overall survival in patients with myelofibrosis and thrombocytopenia.

An oncology nurse shares advice for avoiding exhaustion and soreness when administering subcutaneous injections.

Panelists discuss how balancing effective disease control with managing treatment-related adverse effects in patients with chronic myeloid leukemia (CML) requires a strategic approach that may ...

Panelists discuss the EMERALD trial data, which shows the effectiveness of elacestrant in patients with estrogen receptor 1 (ESR1) mutations, particularly those who were on first-line CDK 4/6 ...

Panelists discuss the safety profile and adverse effects of elacestrant, highlighting its relatively mild nausea and ease of administration compared with other endocrine therapies.

Panelists discuss how molecular testing and liquid biopsies are crucial for tracking estrogen receptor 1 (ESR1) mutations in ...

A nurse practitioner gives her advice for managing adverse events during treatment with talquetamab for multiple myeloma.

Panelists discuss the importance of using liquid biopsy for detecting estrogen receptor 1 (ESR1) mutations rather than ...

The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC ...

Traditionally, HER2 status has been determined by immunohistochemistry (IHC) and in situ hybridization (ISH), distinguishing ...